Amyris Balanced Scorecard
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Dive Deeper Into the Growth Paths Behind the Analysis
This Amyris Balanced Scorecard Analysis gives you a structured view of the company's financial, customer, internal process, and learning and growth priorities. The page already shows a real preview of the actual deliverable, so you can see the content before buying. Purchase the full version to get the complete ready-to-use analysis.
Benefits
Yield Clarity
Yield Clarity forces Amyris to prove that engineered yeast is making target molecules at commercial yields, not just in the lab. In fermentation, even small gains in titer, yield, and throughput can move unit economics fast: a 10% yield lift on a 100,000 kg annual run adds 10,000 kg of output without extra tank time. That kind of discipline helps expose which strains can support scale and which ones destroy margin.
Scale-Up Discipline
Scale-Up Discipline helps Amyris catch where lab wins break down in pilot and manufacturing runs. In synthetic biology, one failed scale-up can wipe out weeks of output, so the scorecard should track batch success rate, cycle time, and quality deviations. That gives management an early warning on cost overruns and yield loss before they hit cash flow.
Demand Focus
Demand focus helps Amyris compare traction across flavors, fragrances, cosmetics, nutraceuticals, and pharmaceuticals, so 2025 capital can go to the best-selling lines. In 2025, Amyris had no active operating disclosures after its 2023 Chapter 11 case, so the scorecard must track end-market demand and not just lab output. That makes it easier to direct scarce capacity, sales time, and cash to products with real pull.
Sustainability Proof
Amyris's bio-based pitch becomes measurable with a scorecard: renewable feedstock share, waste intensity, and process yield turn sustainability from a claim into data. Amyris filed for Chapter 11 in 2023, so clear proof matters more than branding for customers and partners. For buyers, lower fossil input use and better process efficiency are the real test.
Cash Control
Cash control matters at Amyris because a balanced scorecard can link R&D, manufacturing, and sales to gross margin and cash burn. That matters in long-cycle biotech, where a program can look strong in the lab but still fail the return test if cash use outruns revenue. Amyris filed Chapter 11 in 2023, which shows why tracking burn, margin, and launch timing in one view is critical.
One scorecard to prove Amyris can scale and stop burning cash
Benefits: a balanced scorecard would help Amyris turn science into cash by tying yield, scale-up, demand, and burn to one view. Amyris entered Chapter 11 in 2023 and had no active 2025 operating disclosure, so the main benefit is faster proof of commercial viability and earlier loss control.
| Metric | Latest fact |
|---|---|
| 2025 FY disclosure | Not available |
| Chapter 11 | 2023 |
| Scorecard focus | Yield, scale, demand, cash |
What is included in the product
Detailed Word Document
Editable Excel File
Drawbacks
Lagging Numbers
Lagging metrics can hide Amyris's stress until it is too late: revenue, margin, and retention move slowly in biotech, so a process problem may be months old before the scorecard turns red. Amyris filed for Chapter 11 in August 2023, showing how weak signals can surface after cash pressure is already severe. In this kind of business, monthly cash burn and batch yield often warn earlier than sales.
Metric Overload
Amyris's scorecard can get crowded fast because it spans R&D, pilot scale, manufacturing, and multiple customer segments. When teams track too many KPIs at once, priorities blur and the real issue gets buried. The risk is simple: more metrics can mean less clarity, so a broken unit economic, yield, or cash KPI may get less attention than it needs.
Scale-Up Noise
Scale-Up Noise is a real drawback for Amyris because fermentation output can swing with feedstock quality, contamination, and equipment differences. A single quarterly dashboard can mask the root cause, so the scorecard may look precise while only partly diagnosing failure. Amyris's last public results before its 2023 collapse showed a net loss of about $1.3 billion, which shows how small process misses can scale into major financial damage.
Cost Bias
Cost bias can hurt Amyris when managers chase near-term cuts and underfund strain engineering and platform upgrades. That is costly in synthetic biology, because R&D today can drive lower unit costs and better gross margin later; Amyris' 2023 Chapter 11 showed how weak scaling discipline can erase value fast.
Cross-Market Friction
Cross-market friction is a real drawback for Amyris because one scorecard rarely fits flavors, fragrances, cosmetics, nutraceuticals, and pharmaceuticals equally well. Each market has different quality gates, buying cycles, and margin goals, so a single Balanced Scorecard can blur where execution is strong or weak.
That matters when a cosmetics launch may move in months, while pharma or nutraceutical work can take much longer and face tighter compliance checks. A unified KPI set can push teams to chase one target and miss the product-level economics that drive cash and margin.
Amyris's Weak Scorecard Hides Fast-Moving Cash Risk
Amyris's Balanced Scorecard is weak because FY2025 data are not public, so lagging KPIs, crowded metrics, and cross-market differences can hide failure fast. Its last pre-collapse public filing showed about $1.3 billion net loss and Chapter 11 in August 2023, proving small scale-up misses can turn into cash stress.
| Risk | Data point |
|---|---|
| Disclosure gap | FY2025 not public |
| Financial stress | Net loss about $1.3B |
| Distress event | Chapter 11, Aug 2023 |
Full Version Awaits
Amyris Reference Sources
You're previewing the actual Amyris Balanced Scorecard analysis document, not a sample. The full report you see here is the same file you'll receive after purchase, with all sections and details included. Once you complete checkout, the complete Balanced Scorecard analysis becomes available immediately.
Frequently Asked Questions
It measures whether the company can turn engineered yeast into repeatable commercial output. The most useful KPIs are fermentation yield, cost per kilogram, and batch success rate. On the market side, track customer adoption, renewal rate, and on-time delivery across flavors, fragrances, cosmetics, nutraceuticals, and pharma ingredients. Those indicators show whether the platform is scaling or just consuming cash.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.